OBJECTIVES: To evaluate the performance of the 2013 Pooled Cohort Risk Equation (PCE-ASCVD) for predicting cardiovascular disease (CVD) in an Australian population; to compare this performance with that of three frequently used Framingham-based CVD risk prediction models. DESIGN: Prospective national population-based cohort study. SETTING: 42 randomly selected urban and non-urban areas in six Australian states and the Northern Territory. PARTICIPANTS: 5453 adults aged 40-74 years enrolled in the Australian Diabetes, Obesity and Lifestyle study and followed until November 2011. We excluded participants who had CVD at baseline or for whom data required for risk model calculations were missing. MAIN OUTCOME MEASURES: Predicted and observed 10-...
OBJECTIVE: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
Objective: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
BACKGROUND: Chronic cardiometabolic diseases, including cardiovascular disease (CVD), type 2 diabete...
Background: Multivariable risk prediction equations attempt to quantify an individual's cardiovascul...
Background: The Framingham risk models and pooled cohort equations (PCE) are widely used and advocat...
Effective cardiovascular disease (CVD) prevention relies on timely identification and intervention f...
OBJECTIVE: To develop and recalibrate an Australian 5-year cardiovascular disease (CVD) mortality ri...
Cardiovascular disease (CVD) and type 2 diabetes are two major public health challenges. There is st...
Background - We conducted an independent external validation of three cardiovascular risk score mode...
Estimating absolute risk rather than measurement of blood pressure alone is considered the best way ...
Background: Although the National Vascular Disease Prevention Alliance (NVDPA) guidelines were publi...
BACKGROUND: Indicators of cardiometabolic risk typically include non-clinical factors (e.g., smoking...
OBJECTIVE: To determine how well the current Pharmaceutical Benefits Scheme (PBS) eligibility criter...
Background: The objective of this study was to evaluate the performance of risk scores (Framingham, ...
The research presented by John Mancini and co-authors shows an interesting comparison of CVD risk cl...
OBJECTIVE: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
Objective: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
BACKGROUND: Chronic cardiometabolic diseases, including cardiovascular disease (CVD), type 2 diabete...
Background: Multivariable risk prediction equations attempt to quantify an individual's cardiovascul...
Background: The Framingham risk models and pooled cohort equations (PCE) are widely used and advocat...
Effective cardiovascular disease (CVD) prevention relies on timely identification and intervention f...
OBJECTIVE: To develop and recalibrate an Australian 5-year cardiovascular disease (CVD) mortality ri...
Cardiovascular disease (CVD) and type 2 diabetes are two major public health challenges. There is st...
Background - We conducted an independent external validation of three cardiovascular risk score mode...
Estimating absolute risk rather than measurement of blood pressure alone is considered the best way ...
Background: Although the National Vascular Disease Prevention Alliance (NVDPA) guidelines were publi...
BACKGROUND: Indicators of cardiometabolic risk typically include non-clinical factors (e.g., smoking...
OBJECTIVE: To determine how well the current Pharmaceutical Benefits Scheme (PBS) eligibility criter...
Background: The objective of this study was to evaluate the performance of risk scores (Framingham, ...
The research presented by John Mancini and co-authors shows an interesting comparison of CVD risk cl...
OBJECTIVE: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
Objective: To provide an overview of prediction models for risk of cardiovascular disease (CVD) in t...
BACKGROUND: Chronic cardiometabolic diseases, including cardiovascular disease (CVD), type 2 diabete...